These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36788117)

  • 1. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.
    Ulndreaj A; Sohaei D; Thebault S; Pons-Belda OD; Fernandez-Uriarte A; Campbell C; Cheo D; Stengelin M; Sigal G; Freedman MS; Scarisbrick IA; Prassas I; Diamandis EP
    Diagnosis (Berl); 2023 Aug; 10(3):275-280. PubMed ID: 36788117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective.
    Arslan B; Ayhan Arslan G; Tuncer A; Karabudak R; Sepici Dinçel A
    Bosn J Basic Med Sci; 2022 Sep; 22(5):699-706. PubMed ID: 35490364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
    Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK
    Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
    Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
    Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
    J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of IL-21 in human serum and plasma using ultrasensitive MSD S-PLEX® and Quanterix SiMoA methodologies.
    Poorbaugh J; Samanta T; Bright SW; Sissons SE; Chang CY; Oberoi P; MacDonald AJ; Martin AP; Cox KL; Benschop RJ
    J Immunol Methods; 2019 Mar; 466():9-16. PubMed ID: 30590020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension.
    Engel S; Halcour J; Ellwardt E; Uphaus T; Steffen F; Zipp F; Bittner S; Luessi F
    Fluids Barriers CNS; 2023 Jan; 20(1):3. PubMed ID: 36631830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.
    Verberk IMW; Koel-Simmelink M; Twaalfhoven H; Vrenken H; Korth C; Killestein J; Teunissen CE; Bridel C
    Mult Scler Relat Disord; 2021 May; 50():102840. PubMed ID: 33626430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients.
    Vecchio D; Puricelli C; Malucchi S; Virgilio E; Martire S; Perga S; Passarelli F; Valentino P; Di Sapio A; Cantello R; Dianzani U; Comi C
    Mult Scler Relat Disord; 2024 Feb; 82():105412. PubMed ID: 38198989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of Two Analytical Approaches for the Quantification of Neurofilament Light Chain, a Biomarker of Axonal Damage in Multiple Sclerosis.
    Pafiti A; Krashias G; Tzartos J; Tzartos S; Stergiou C; Gaglia E; Smoleski I; Christodoulou C; Pantzaris M; Lambrianides A
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis.
    Alagaratnam J; von Widekind S; De Francesco D; Underwood J; Edison P; Winston A; Zetterberg H; Fidler S
    BMJ Neurol Open; 2021; 3(1):e000143. PubMed ID: 34223154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
    Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
    Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    Martin SJ; McGlasson S; Hunt D; Overell J
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.